Pfizer's CTI Requests Proposals for Small-Molecule Accelerator (SMA) Initiative

UMCCTS and Pfizer CTI image

Click here for a printable PDF

CTI, or Pfizer's Centers for Therapeutic Innovation, is a unique program that partners with leading academic medical centers and foundations nationwide in an effort to speed the translation of novel targets to the clinic. CTI's goal is to identify new compounds and accelerate research from validated target to proof-of-mechanism in the clinic.

Advantages to Collaborating with CTI

A partnership with CTI may include collaborative use of Pfizer's technologies and compound library, publishing rights, and financial awards in the form of milestone and royalty payments for successful programs, in addition to providing appropriate funds for carrying out the collaborative work.

CTI's foundation partners include:

  • Alliance for Lupus Research
  • Alzheimer's Drug Discovery Foundation
  • Crohn's and Colitis Foundation of America
New Initiative: CTI's Small-molecule Accelerator
  • In addition to the usual small-molecule request for proposals, CTI is introducing a Small Molecule Accelerator (SMA) Initiative
  • The CTI SMA program is based on a select set of characterized lead-like small-molecule compounds with activity and selectivity for established targets
  • The compounds within the SMA:
    • Are selective pharmacological modulators representative of a lead quality series (Details regarding small-molecule inhibitors included in the SMA will be shared upon request); and
    • Are suitable for cel-based target validation assays at a minimum; some are suitable for preclinical in-vivo experiments; and may have been through in-vivo toxicology screens
  • Proposals must delineate a plan to evaluate one or a small number of these compounds in a specific assay in the laboratory of the Investigator, evaluating a target-related hypothesis
List of Biological Target/Class
Biological Target Class   Biological Target Class
CREB binding protein bromodomain inhibitor Bromodomain   LTK inhibitor Kinase
LYPLA1 inhibitor Serine hydrolase    TYRO3 (SKY) inhibitor  Kinase
Neutral endopeptidase inhibitor Metallo-protease   PIK3C2A inhibitor  Kinase
Selective androgen receptor modulator  Nuclear hormone receptor    P13K/mTOR inhibitor  Kinase
GPR119 agonist  GPCR    MAP4K4 inhibitor  Kinase
GPR44 (CRTH2) antagonist  GPCR    ASK1 inhibitor  Kinase
KATII (Aminoadipate aminotransferase) inhibitor  Amino-transferase    RIP1 inhibitor  Kinase
NaCT  SLC    ITK allosteric inhibitor  Kinase
PDE1 inhibitor  PDE    V1a antagonist  GPCR
PDE7 inhibitor  PDE    Thrombin activatable fibrinolysis inhibitor (TAFla)  Carboxy peptidase
PDE8 inhibitor  PDE    hPGDS inhibitor  GST
PDE11 inhibitor  PDE    ASIC1a antagonist  Ion channel
pan MARK inhibitor  Kinase   P2X3 inhibitor  Ion channel
      P2X4 inhibitor  Ion channel

 

Pre-Proposal Submission Process

Submission entails a brief, non-confidential 2-3 page overview of the target, mechanism (including evidence for disease linkage), and the proposed therapeutic drug. At a high-level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

All researchers and clinicians whose work meets these criteria are invited to apply.

For more information or questions, please contact Venkat Reddy at Pfizer or Nate Hafer at UMMS.

Thank you for your interest in Pfizer's Centers for Therapeutic Innovation.  We look forward to your ideas.